Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)

Summary

The main purpose of this study is to assess the ability of a repeated high-frequency site-based computerized cognitive assessment to evaluate the potential treatment effects of donepezil (MK-0000) compared with placebo among participants with mild cognitive impairment (MCI) or mild Alzheimer's Disease (AD). The primary study hypothesis is that the average percentage of correct responses on one card learning (OCL) task will be ≥2 percentage points in participants receiving donepezil compared with participants receiving placebo.

Timeline

Start

2021-03-23

Primary completion

2023-01-20

Completion

2023-02-06

Drugs

Indications